Bill Text: TX SB173 | 2015-2016 | 84th Legislature | Enrolled


Bill Title: Relating to the designation for criminal prosecution and other purposes of certain chemicals commonly referred to as synthetic cannabinoids as controlled substances and controlled substance analogues under the Texas Controlled Substances Act.

Spectrum: Slight Partisan Bill (Republican 3-1)

Status: (Passed) 2015-05-22 - Effective on 9/1/15 [SB173 Detail]

Download: Texas-2015-SB173-Enrolled.html
 
 
  S.B. No. 173
 
 
 
 
AN ACT
  relating to the designation for criminal prosecution and other
  purposes of certain chemicals commonly referred to as synthetic
  cannabinoids as controlled substances and controlled substance
  analogues under the Texas Controlled Substances Act.
         BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
         SECTION 1.  Sections 481.002(5) and (6), Health and Safety
  Code, are amended to read as follows:
               (5)  "Controlled substance" means a substance,
  including a drug, an adulterant, and a dilutant, listed in
  Schedules I through V or Penalty Group [Groups] 1, 1-A, [or] 2, 2-A,
  3, or [through] 4. The term includes the aggregate weight of any
  mixture, solution, or other substance containing a controlled
  substance.
               (6)  "Controlled substance analogue" means:
                     (A)  a substance with a chemical structure
  substantially similar to the chemical structure of a controlled
  substance in Schedule I or II or Penalty Group 1, 1-A, [or] 2, or
  2-A; or
                     (B)  a substance specifically designed to produce
  an effect substantially similar to, or greater than, the effect of a
  controlled substance in Schedule I or II or Penalty Group 1, 1-A,
  [or] 2, or 2-A.
         SECTION 2.  Section 481.1031, Health and Safety Code, is
  amended to read as follows:
         Sec. 481.1031.  PENALTY GROUP 2-A.  (a)  In this section:
               (1)  "Core component" is one of the following:
  azaindole, benzimidazole, benzothiazole, carbazole, imidazole,
  indane, indazole, indene, indole, pyrazole, pyrazolopyridine,
  pyridine, or pyrrole.
               (2)  "Group A component" is one of the following:
  adamantane, benzene, cycloalkylmethyl, isoquinoline,
  methylpiperazine, naphthalene, phenyl, quinoline,
  tetrahydronaphthalene, tetramethylcyclopropane, amino oxobutane,
  amino dimethyl oxobutane, amino phenyl oxopropane, methyl methoxy
  oxobutane, methoxy dimethyl oxobutane, methoxy phenyl oxopropane,
  or an amino acid.
               (3)  "Link component" is one of the following
  functional groups: carboxamide, carboxylate, hydrazide, methanone
  (ketone), ethanone, methanediyl (methylene bridge), or methine.
         (b)  Penalty Group 2-A consists of any material, compound,
  mixture, or preparation that contains any quantity of a natural or
  synthetic chemical substance, including its salts, isomers, and
  salts of isomers, listed by name in this subsection or contained
  within one of the structural classes defined in this subsection:
               (1)  WIN-55,212-2;
               (2)  Cyclohexylphenol:  any compound [that is a
  cannabinoid receptor agonist and mimics the pharmacological effect
  of naturally occurring cannabinoids, including:
               [naphthoylindoles structurally derived from
  3-(1-naphthoyl)indole by substitution at the nitrogen atom of the
  indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
  or 2-(4-morpholinyl)ethyl, whether or not further substituted in
  the indole ring to any extent, whether or not substituted in the
  napthyl ring to any extent, including:
                     [AM-2201;
                     [JWH-004;
                     [JWH-007;
                     [JWH-009;
                     [JWH-015;
                     [JWH-016;
                     [JWH-018;
                     [JWH-019;
                     [JWH-020;
                     [JWH-046;
                     [JWH-047;
                     [JWH-048;
                     [JWH-049;
                     [JWH-050;
                     [JWH-073;
                     [JWH-076;
                     [JWH-079;
                     [JWH-080;
                     [JWH-081;
                     [JWH-082;
                     [JWH-083;
                     [JWH-093;
                     [JWH-094;
                     [JWH-095;
                     [JWH-096;
                     [JWH-097;
                     [JWH-098;
                     [JWH-099;
                     [JWH-100;
                     [JWH-116;
                     [JWH-122;
                     [JWH-148;
                     [JWH-149;
                     [JWH-153;
                     [JWH-159;
                     [JWH-164;
                     [JWH-165;
                     [JWH-166;
                     [JWH-180;
                     [JWH-181;
                     [JWH-182;
                     [JWH-189;
                     [JWH-193;
                     [JWH-198;
                     [JWH-200;
                     [JWH-210;
                     [JWH-211;
                     [JWH-212;
                     [JWH-213;
                     [JWH-234;
                     [JWH-235;
                     [JWH-239;
                     [JWH-240;
                     [JWH-241;
                     [JWH-242;
                     [JWH-258;
                     [JWH-259;
                     [JWH-260;
                     [JWH-262;
                     [JWH-267;
                     [JWH-386;
                     [JWH-387;
                     [JWH-394;
                     [JWH-395;
                     [JWH-397;
                     [JWH-398;
                     [JWH-399;
                     [JWH-400;
                     [JWH-412;
                     [JWH-413; and
                     [JWH-414;
               [naphthylmethylindones structurally derived from
  1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen
  atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl,
  cycloalkylethyl, or 2-(4-morpholinyl)ethyl, whether or not further
  substituted in the indole ring to any extent, whether or not
  substituted in the naphthyl ring to any extent, including:
                     [JWH-175;
                     [JWH-184;
                     [JWH-185;
                     [JWH-192;
                     [JWH-194;
                     [JWH-195;
                     [JWH-196;
                     [JWH-197; and
                     [JWH-199;
               [naphthoylpyrroles structurally derived from
  3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the
  pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
  or 2-(4-morpholinyl)ethyl, whether or not further substituted in
  the pyrrole ring to any extent, whether or not substituted in the
  naphthyl ring to any extent, including:
                     [JWH-030;
                     [JWH-145;
                     [JWH-146;
                     [JWH-147;
                     [JWH-150;
                     [JWH-156;
                     [JWH-243;
                     [JWH-244;
                     [JWH-245;
                     [JWH-246;
                     [JWH-292;
                     [JWH-293;
                     [JWH-307;
                     [JWH-308;
                     [JWH-309;
                     [JWH-346;
                     [JWH-347;
                     [JWH-348;
                     [JWH-363;
                     [JWH-364;
                     [JWH-365;
                     [JWH-366;
                     [JWH-367;
                     [JWH-368;
                     [JWH-369;
                     [JWH-370;
                     [JWH-371;
                     [JWH-372;
                     [JWH-373; and
                     [JWH-392;
               [naphthylmethylindenes structurally derived from
  1-(1-naphthylmethyl)indene by substitution at the 3-position of
  the indene ring by alkyl, alkenyl, cycloalkylmethyl,
  cycloalkylethyl, or 2-(4-morpholinyl)ethyl, whether or not further
  substituted in the indene ring to any extent, whether or not
  substituted in the naphthyl ring to any extent, including:
                     [JWH-171;
                     [JWH-172;
                     [JWH-173; and
                     [JWH-176;
               [phenylacetylindoles structurally derived from
  3-phenylacetylindole by substitution at the nitrogen atom of the
  indole ring with alkyl, alkenyl, cycloalkylmethyl,
  cycloalkylethyl, or 2-(4-morpholinyl)ethyl, whether or not further
  substituted in the indole ring to any extent, whether or not
  substituted in the phenyl ring to any extent, including:
                     [AM-694;
                     [AM-1241;
                     [JWH-167;
                     [JWH-203;
                     [JWH-204;
                     [JWH-205;
                     [JWH-206;
                     [JWH-208;
                     [JWH-237;
                     [JWH-248;
                     [JWH-249;
                     [JWH-250;
                     [JWH-251;
                     [JWH-252;
                     [JWH-253;
                     [JWH-302;
                     [JWH-303;
                     [JWH-305;
                     [JWH-306;
                     [JWH-311;
                     [JWH-312;
                     [JWH-313;
                     [JWH-314; and
                     [JWH-315;
               [cyclohexylphenols] structurally derived from
  2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of
  the phenolic ring [by alkyl], (N-methylpiperidin-2-yl)alkyl,
  (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl [alkenyl,
  cycloalkylmethyl, cycloalkylethyl, or 2-(4-morpholinyl)ethyl],
  whether or not substituted in the cyclohexyl ring to any extent,
  including:
                     JWH-337;
                     JWH-344;
                     CP-55,940;
                     CP-47,497; and
                     analogues of CP-47,497;
               (3)  Cannabinol[, including VII, V, VIII, I, II, III,
  IV, IX, X, XI, XII, XIII, XV, and XVI;
                     [JWH-337;
                     [JWH-344;
                     [JWH-345; and
                     [JWH-405; and
               [cannabinol] derivatives, except where contained in
  marihuana, including tetrahydro derivatives of cannabinol and
  3-alkyl homologues of cannabinol or of its tetrahydro derivatives,
  such as:
                     Nabilone;
                     HU-210; and
                     HU-211;
               (4)  Tetramethylcyclopropyl thiazole:  any compound
  structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-
  2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen
  atom of the thiazole ring, whether or not further substituted in the
  thiazole ring to any extent, whether or not substituted in the
  tetramethylcyclopropyl ring to any extent, including:
                     A-836,339;
               (5)  any compound containing a core component
  substituted at the 1-position to any extent, and substituted at the
  3-position with a link component attached to a group A component,
  whether or not the core component or group A component are further
  substituted to any extent, including:
                     Naphthoylindane;
                     Naphthoylindazole (THJ-018);
                     Naphthyl methyl indene (JWH-171);
                     Naphthoylindole (JWH-018);
                     Quinolinoyl pyrazole carboxylate (Quinolinyl
  fluoropentyl fluorophenyl pyrazole carboxylate);
                     Naphthoyl pyrazolopyridine; and
                     Naphthoylpyrrole (JWH-030);
               (6)  any compound containing a core component
  substituted at the 1-position to any extent, and substituted at the
  2-position with a link component attached to a group A component,
  whether or not the core component or group A component are further
  substituted to any extent, including:
                     Naphthoylbenzimidazole (JWH-018 Benzimidazole);
  and
                     Naphthoylimidazole;
               (7)  any compound containing a core component
  substituted at the 3-position to any extent, and substituted at the
  2-position with a link component attached to a group A component,
  whether or not the core component or group A component are further
  substituted to any extent, including:
                     Naphthoyl benzothiazole; and
               (8)  any compound containing a core component
  substituted at the 9-position to any extent, and substituted at the
  3-position with a link component attached to a group A component,
  whether or not the core component or group A component are further
  substituted to any extent, including:
                     Naphthoylcarbazole (EG-018) [and
                     [WIN-55,212-2].
         SECTION 3.  Section 481.106, Health and Safety Code, is
  amended to read as follows:
         Sec. 481.106.  CLASSIFICATION OF CONTROLLED SUBSTANCE
  ANALOGUE. For the purposes of the prosecution of an offense under
  this subchapter involving the manufacture, delivery, or possession
  of a controlled substance, Penalty Groups 1, 1-A, [and] 2, and 2-A
  include a controlled substance analogue that:
               (1)  has a chemical structure substantially similar to
  the chemical structure of a controlled substance listed in the
  applicable penalty group; or
               (2)  is specifically designed to produce an effect
  substantially similar to, or greater than, a controlled substance
  listed in the applicable penalty group.
         SECTION 4.  The change in law made by this Act applies only
  to an offense committed on or after the effective date of this Act.
  An offense committed before the effective date of this Act is
  governed by the law in effect on the date the offense was committed,
  and the former law is continued in effect for that purpose. For
  purposes of this section, an offense was committed before the
  effective date of this Act if any element of the offense occurred
  before that date.
         SECTION 5.  This Act takes effect September 1, 2015.
 
 
 
 
 
  ______________________________ ______________________________
     President of the Senate Speaker of the House     
 
         I hereby certify that S.B. No. 173 passed the Senate on
  March 24, 2015, by the following vote:  Yeas 31, Nays 0.
 
 
  ______________________________
  Secretary of the Senate    
 
         I hereby certify that S.B. No. 173 passed the House on
  May 11, 2015, by the following vote:  Yeas 136, Nays 0, one
  present not voting.
 
 
  ______________________________
  Chief Clerk of the House   
 
 
 
  Approved:
 
  ______________________________ 
              Date
 
 
  ______________________________ 
            Governor
feedback